Technical Data
NALP2 (NACHT, LRR and PYD Domains-containing Protein 2, Nucleotide-binding site Protein 1, PYRIN Domain and NACHT Domain-containing Protein 1, PYRIN-containing APAF1-like Protein 2, NLRP2, NBS1, PAN1, PYPAF2)
NALP2 belongs to a family of cytoplasmic proteins that have been implicated in cell responses to apoptotic and inflammatory stimuli. Unlike the prototypical NALP protein NALP1, NALP2 only contains a NACHT domain, leucine rich repeat (LRR), and pyrin-containing domain (PYD). This protein interacts with the adapter protein ASC in addition to CARD8 and caspase-1 to form an inflammasome with high proIL-1b-processing activity and is thought to function as a modulator of NF-kB and procaspase-1 activation in macrophages. It has also been suggested that NALP2, in addition to other NALP family members, can act as innate sensors of pathogens in a manner similar to the toll-like receptors (TLRs). At least two alternatively spliced transcript variants encoding distinct isoforms have been found for NALP2.

Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1-2ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
PC-3 cell lysate

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
50ug-20CBlue IceHumanRabbit
As reported
Synthetic peptide corresponding to 12aa near the C-terminus of human NALP2.
Purified by immunoaffinity chromatography.
Supplied as a liquid in PBS, 0.02% sodium azide.
Recognizes human NALP2. Species Crossreactivity: mouse and rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Tschopp, J. et al. Nat. Rev. Mol. Cell Biol. 4, 95 (2003). 2. Bruey, JM. et al. J. Biol. Chem. 279, 51897 (2004). 3. Agostini, L. et al. Immunity 20, 319 (2004). 4. Martinon, F. et al. TRENDS Imm. 26, 447 (2005).